ArticleThe Journal of international medical research2016
The effect of etanercept on vascular endothelial growth factor production by cutaneous mesenchymal stem cells from patients with psoriasis.
Article in The Journal of international medical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- Effects of Adalimumab on Mitochondria of Psoriatic Mesenchymal Stem Cells.Journal of cellular and molecular medicine · 2025Article
- Mesenchymal Stem Cells Profile in Adult Atopic Dermatitis and Effect of IL4-IL13 Inflammatory Pathway Inhibition In Vivo: Prospective Case-Control Study.Journal of clinical medicine · 2022Article
- The efficacy of in vivo administration of Apremilast on mesenchymal stem cells derived from psoriatic patients.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Article
- Anti-TNF- αtreatment-related pathways and biomarkers revealed by transcriptome analysis in Chinese psoriasis patients.BMC systems biology · 2019Article
- Dermal mesenchymal stem cells: a resource of migration-associated function in psoriasis?Stem cell research & therapy · 2019Article
- Mesenchymal Stromal Cells from the Epidermis and Dermis of Psoriasis Patients: Morphology, Immunophenotype, Differentiation Patterns, and Regulation of T Cell Proliferation.Stem cells international · 2019Article
- Pathogenetic Characteristics of Mesenchymal Stem Cells in Hidradenitis Suppurativa.JAMA dermatology · 2018Article
- Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows.Frontiers in immunology · 2018Review
- Anti-angiogenic effects of biotechnological therapies in rheumatic diseases.Biologics : targets & therapy · 2017Review
- Role of mesenchymal stem cells in the pathogenesis of psoriasis: current perspectives.Psoriasis (Auckland, N.Z.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate prospectively the effect of etanercept (a tumour necrosis factor [TNF]-α inhibitor) on vascular endothelial growth factor (VEGF) production by mesenchymal stem cells (MSC) from patients with psoriasis.
methodsMSCs from lesional and perilesional skin were isolated, cultured and characterized. VEGF production was evaluated at baseline and after 12 weeks' etanercept treatment.
resultsEtanercept treatment resulted in significant reductions in VEGF production compared with baseline in both lesional MSCs (256.42 ± 3.07 pg/ml per 10
conclusionsEtanercept reduces the production of VEGF in MSCs, which may modulate angiogenesis and contributes towards preventing the start of the "psoriatic march".
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.